Contrasting CASI Pharmaceuticals (NASDAQ:CASI) & PolyPid (NASDAQ:PYPD)

CASI Pharmaceuticals (NASDAQ:CASI) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Risk & Volatility

CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Profitability

This table compares CASI Pharmaceuticals and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
PolyPid	N/A	-241.96%	-126.91%

Institutional & Insider Ownership

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares CASI Pharmaceuticals and PolyPid”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85 million	0.10	-$39.26 million	($3.01)	-0.07
PolyPid	N/A	N/A	-$34.17 million	($1.91)	-2.65

PolyPid has lower revenue, but higher earnings than CASI Pharmaceuticals. PolyPid is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for CASI Pharmaceuticals and PolyPid, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1	0	1	0	2.00
PolyPid	1	0	5	0	2.67

CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. PolyPid has a consensus target price of $12.25, suggesting a potential upside of 141.62%. Given CASI Pharmaceuticals’ higher possible upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than PolyPid.

Summary

PolyPid beats CASI Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.